Your browser doesn't support javascript.
loading
Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial.
Chaitman, Bernard R; Cyr, Derek D; Alexander, Karen P; Pracon, Radoslaw; Bainey, Kevin R; Mathew, Anoop; Acharya, Anjali; Kunichoff, Dennis F; Fleg, Jerome L; Lopes, Renato D; Sidhu, Mandeep S; Anthopolos, Rebecca; Rockhold, Frank W; Stone, Gregg W; Maron, David J; Hochman, Judith S; Bangalore, Sripal.
Afiliação
  • Chaitman BR; Saint Louis University School of Medicine, MO (B.R.C.).
  • Cyr DD; Duke Clinical Research Institute and Duke University, Durham, NC (D.D.C., K.P.A., R.D.L., F.W.R.).
  • Alexander KP; Duke Clinical Research Institute and Duke University, Durham, NC (D.D.C., K.P.A., R.D.L., F.W.R.).
  • Pracon R; Coronary and Structural Heart Diseases Department, Institute of Cardiology, Mazowieckie, Poland (R.P.).
  • Bainey KR; Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada (K.R.B.).
  • Mathew A; MOSC Medical College Hospital, Kolenchery, India (A.M.).
  • Acharya A; Jacobi Medical Center, Bronx, NY (A.A.).
  • Kunichoff DF; Harvard TH Chan School of Public Health, Boston, MA (D.F.K.).
  • Fleg JL; National National Heart Lung and Blood Institute, Bethesda, MD (J.L.F.).
  • Lopes RD; Duke Clinical Research Institute and Duke University, Durham, NC (D.D.C., K.P.A., R.D.L., F.W.R.).
  • Sidhu MS; Albany Medical College, NY (M.S.S.).
  • Anthopolos R; NYU Grossman School of Medicine (R.A., J.S.H., S.B.).
  • Rockhold FW; Duke Clinical Research Institute and Duke University, Durham, NC (D.D.C., K.P.A., R.D.L., F.W.R.).
  • Stone GW; Icahn School of Medicine at Mount Sinai, New York, NY (G.W.S.).
  • Maron DJ; Stanford University School of Medicine, CA (D.J.M.).
  • Hochman JS; NYU Grossman School of Medicine (R.A., J.S.H., S.B.).
  • Bangalore S; NYU Grossman School of Medicine (R.A., J.S.H., S.B.).
Circ Cardiovasc Interv ; 15(8): e012103, 2022 08.
Article em En | MEDLINE | ID: mdl-35973009
BACKGROUND: ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) reported an initial invasive treatment strategy did not reduce the risk of death or nonfatal myocardial infarction (MI) compared with a conservative treatment strategy in patients with advanced chronic kidney disease, stable coronary disease, and moderate or severe myocardial ischemia. The cumulative frequency of different MI type after randomization and subsequent prognosis have not been reported. METHODS: MI classification was based on the Third Universal Definition for MI. For procedural MI, the primary MI definition used creatine kinase-MB as the preferred biomarker, whereas the secondary MI definition used cTn (cardiac troponin); both definitions included elevated biomarker-only events with higher thresholds than nonprocedural MIs. The cumulative frequency of MI type according to treatment strategy was determined. The association of MI with subsequent all-cause death and new dialysis initiation was assessed by treating MI as a time-dependent covariate. RESULTS: The 3-year incidence of type 1 or 2 MI with the primary MI definition was 11.2% in invasive treatment strategy and 13.6% in conservative treatment strategy (hazard ratio [HR], 0.66 [95% CI, 0.42-1.02]). Procedural MIs were more frequent in invasive treatment strategy and accounted for 9.8% and 28.3% of all MIs with the primary and secondary MI definitions, respectively. Patients had an increased risk of all-cause death after type 1 MI (adjusted HR, 4.35 [95% CI, 2.73-6.93]) and after procedural MI with the primary (adjusted HR, 2.75 [95% CI, 0.99-7.60]) and secondary MI definitions (adjusted HR, 2.91 [95% CI, 1.73-4.88]). Dialysis initiation was increased after a type 1 MI (HR, 6.45 [95% CI, 2.59-16.08]) compared with patients without an MI. CONCLUSIONS: In ISCHEMIA-CKD, the invasive treatment strategy had higher rates of procedural MIs, particularly with the secondary MI definition, and lower rates of type 1 and 2 MIs. Procedural MIs, type 1 MIs, and type 2 MIs were associated with increased risk of subsequent death. Type 1 MI increased the risk of dialysis initiation. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01985360.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Insuficiência Renal Crônica / Infarto do Miocárdio Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença da Artéria Coronariana / Insuficiência Renal Crônica / Infarto do Miocárdio Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article